Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events

Subsequent Events
9 Months Ended
Sep. 30, 2016
Subsequent Events [Abstract]  
Subsequent Events

Note 9 - Subsequent Events


On October 22, 2016, the Company issued 1,000 shares of common stock to an employee for vested grant.


On October 18, 2016, Iomab-B, was granted orphan designation in the European Union (EU) by the European Medicines Agency (EMA).


On October 4, 2016, the Company sold through an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $1.25. In addition, Actinium granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of common stock solely to cover over-allotments, if any. The Company received $10 million in gross proceeds in the offering, increasing the Company's cash on hand to $25,527,385, before deducting offering expenses.


Subsequent to October 1, 2016, the Company granted two employees a total of 20,000 options to purchase the Company’s common stock.